Blue Cross of California v. Smithkline Beecham Clinical Laboratories, Inc.

108 F. Supp. 2d 84, 1999 U.S. Dist. LEXIS 22230
CourtDistrict Court, D. Connecticut
DecidedJuly 2, 1999
DocketMDL 1210, CV3:97CV17795 AVC
StatusPublished
Cited by10 cases

This text of 108 F. Supp. 2d 84 (Blue Cross of California v. Smithkline Beecham Clinical Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Blue Cross of California v. Smithkline Beecham Clinical Laboratories, Inc., 108 F. Supp. 2d 84, 1999 U.S. Dist. LEXIS 22230 (D. Conn. 1999).

Opinion

*88 RULING ON THE DEFENDANT’S MOTIONS TO DISMISS THE SECOND AMENDED COMPLAINT AND THE AMENDED CLASS ACTION COMPLAINT

COVELLO, Chief Judge.

This is an action for legal and equitable relief in which the plaintiffs, thirty-seven health care insurers and payers for health care services, four health care plans, and six individuals, claim that the defendant, SmithKline Beecham Clinical Laboratories, Inc. (“SBCL”), engaged in, inter alia, fraudulent billing practices. 1 Specifically, the second amended complaint and the amended class action complaint assert causes of action under the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. § 1961 et seq. (“RICO”), the Employee Retirement Income Security Act, 29 U.S.C. § 1001 et seq. (“ERISA”), and under common law tenets sounding in fraud, unjust enrichment and restitution. 2

Pursuant to Federal Rule of Civil Procedure 12(b)(6), SBCL now moves to dismiss both the second amended complaint and some, but’ not all, of the counts in the *89 consolidated amended class action complaint.

The issues presented are: 1) whether the second amended complaint and the amended class action complaint allege facts sufficient to establish a RICO cause of action; 3 and, if so, 2) whether the class plaintiffs’ allegations of fraud underlying their RICO claim are alleged with sufficient particularity as required by Federal Rule of Civil Procedure 9(b); 3) whether the plaintiff insurers have alleged facts sufficient to establish that they are “fiduciaries” within the meaning of ERISA, so as to have standing to assert their ERISA claims against SBCL; and, if not, 4) whether the court should recognize a federal common law cause of action for equitable relief in favor of the plaintiff insurers who are not “fiduciaries” within the meaning of ERISA; 5) whether the plaintiff insurers’ state common law causes of action for fraud, unjust enrichment and restitution are preempted by ERISA; 6) whether the court should create a common law cause of action for unjust enrichment or restitution on behalf of the class plaintiffs who already have standing to assert an ERISA claim against SBCL; and 7) whether the state law causes of action for conversion, unjust enrichment, and for violations of the Pennsylvania Unfair Trade Practices Act asserted by the four employee benefit plans identified in the eonsoli-dated amended class action complaint are preempted by ERISA. 4

For the reasons hereinafter set forth, the court concludes that: 1) the complaints fail to state a cognizable RICO cause of action; 2) only six of the thirty-seven plaintiff insurers have alleged facts sufficient to establish, at this stage of the litigation, that they are “fiduciaries” within the meaning of ERISA with standing to sue SBCL; 3) in light of the court’s conclusion that the class plaintiffs’ RICO cause of action should be dismissed, it need not address whether the class plaintiffs’ allegations of fraud fulfill the requirements of Federal Rule of Civil Procedure 9(b); 4) it should not create a federal common law cause of action for equitable relief on behalf of those insurers who are not “fiduciaries” within the meaning of ERISA; 5) the plaintiff insurers’ state common law causes of action for fraud, unjust enrichment and restitution are preempted by ERISA, to the extent they seek relief for payments made to SBCL on behalf of ERISA-qualifying benefit plans; 6) the court should not create a federal common law cause of action for unjust enrichment or restitution on behalf of parties who already have a cause of action against SBCL under ERISA; and 7) the state law causes of action for conversion, unjust enrichment and for violations of the Pennsylvania Unfair Trade Practices Act, *90 asserted by the four employee benefit plans, are preempted by ERISA.

Accordingly, the defendant’s motion to dismiss the second amended complaint is GRANTED in part and DENIED in part, and its motion to dismiss counts I and III of the consolidated amended class action complaint and counts IV, V, and VI, of the consolidated class action complaint to the extent those claims are asserted by the four employee benefit plans, is GRANTED.

FACTS

On August 19, 1997, thirty-seven insurance companies initiated this lawsuit.

On June 11, 1998, the court dismissed the plaintiff insurers’ amended complaint and the individual plaintiffs (now the “class plaintiffs”) complaint, but gave them leave to re-file their claims against SBCL.

On September 18, 1998, the plaintiff insurers filed their second amended complaint against SBCL.

On September 29, 1998, the “class plaintiffs” 5 filed their consolidated amended class action complaint.

The second amended complaint and the amended class action complaint disclose that the plaintiff insurers are thirty-seven health insurers 6 and payers for health care services, and the “class plaintiffs” 7 are four employer benefit plans, one corporation 8 and six individuals. SBCL is a subsidiary of SmithKline Beecham pic, a British corporation and incorporated in the state of Delaware. SBCL owns and oper *91 ates one of the nation’s largest chains of clinical laboratories.

The gravamen of the second amended complaint and the RICO Case Statement 9 is that from 1989 until 1995, SBCL engaged in fraudulent billing practices that resulted in millions of dollars in losses to the plaintiff insurers.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hill v. Opus Corp.
841 F. Supp. 2d 1070 (C.D. California, 2011)
Puerto Rico American Insurance v. Burgos
867 F. Supp. 2d 216 (D. Puerto Rico, 2011)
CRABHOUSE OF DOUGLASTON INC. v. Newsday, Inc.
801 F. Supp. 2d 64 (E.D. New York, 2011)
Allstate Insurance v. Rozenberg
590 F. Supp. 2d 384 (E.D. New York, 2008)
In Re Managed Care Litigation
298 F. Supp. 2d 1259 (S.D. Florida, 2003)
In Re Pharmaceutical Industry Average Wholesale Price Litigation
263 F. Supp. 2d 172 (D. Massachusetts, 2003)
Martinez v. Martinez
207 F. Supp. 2d 1303 (D. New Mexico, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
108 F. Supp. 2d 84, 1999 U.S. Dist. LEXIS 22230, Counsel Stack Legal Research, https://law.counselstack.com/opinion/blue-cross-of-california-v-smithkline-beecham-clinical-laboratories-inc-ctd-1999.